中国高速传动(00658)发布公告，公司已邀请数间核数师事务所就公司核数师职位比选，最终三间事务 所已于规定期限前提交比选文件，经考虑及公司审核委员会推荐建议后，国卫会计师事务所有限公司 (国卫)已获委任为集团新任核数师，自2025年9月6日起生效，以填补公司核数师的临时空缺，任期直至 公司下届股东周年大会结束为止(委任)。 ...

Group 1 - Hong Kong Broadband (01310) and China Mobile Hong Kong announced the resignation of Yang Zhuguang from multiple positions including Executive Director and Group CEO [1] - Ling Hao has been appointed as the new Executive Director and Chairman of the Board, while Li Xin has been appointed as Executive Director and Group CEO [1] - Changes in the Board Committees include Ling Hao as the Chairman of the Nomination Committee, Li Xin as the Chairman of the Risk Committee, and Lei Li Qun as a member of the Compensation Committee [1] Group 2 - Li Xin has been appointed as the new authorized representative under the Hong Kong Stock Exchange Listing Rules [2] - Li Xin has also been appointed as the new authorized representative under the Companies Ordinance [2] Group 3 - Guohao Lawyers (Hong Kong) has been appointed as the new legal representative for procedural documents under the Listing Rules [3]

智通财经APP讯，来凯医药-B(02105)发布公告，该公司于2025年9月5日发行合计273万股普通股以满足 根据2024年股份奖励计划授予的RSU的归属。 ...

格隆汇9月7日丨万洲国际(00288.HK)发布公告，2025年9月5日(纽约时间)，董事会主席兼执行董事万隆 先生已同意于史密斯菲尔德二次发行中按发售价及与所发售的其他史密斯菲尔德股份相同的条款购买 180万股史密斯菲尔德股份，占史密斯菲尔德二次发行中所发售的史密斯菲尔德股份约8.01%及截至本 公告日期史密斯菲尔德已发行股本总额约0.46%。万先生就认购事项支付的代价约为4,185万美元(相当 于约3.2643亿港元)。万先生以来自商业银行的贷款融资为认购事项提供资金。 ...

Group 1 - Hong Kong Broadband (01310) and China Mobile Hong Kong announced the resignation of Yang Zhuguang from multiple positions including Executive Director and Group CEO [1] - Ling Hao has been appointed as the new Executive Director and Chairman of the Board, while Li Xin has been appointed as Executive Director and Group CEO [1] - Changes in the Board Committees include Ling Hao as the Chairman of the Nomination Committee and Li Xin as the Chairman of the Risk Committee [1] Group 2 - Li Xin has been appointed as the new authorized representative under the Hong Kong Stock Exchange Listing Rules [2] - Li Xin has also been appointed as the new authorized representative under the Companies Ordinance [2] - Guohao Lawyers (Hong Kong) has been appointed as the new legal representative for procedural documents under the Listing Rules [3]

格隆汇9月7日丨香港宽频(01310.HK)发布公告，自2025年9月5日起：1.杨主光已辞任公司执行董事、执 行副主席、集团行政总裁、提名委员会成员及环境、社会及管治委员会成员；2.凌浩已获委任为执行董 事兼董事会主席；3.钟郝仪已卸任董事会主席职务，并将继续担任独立非执行董事；4.李昕已获委任为 执行董事兼集团行政总裁；5.雷立群已获委任为执行董事以及；6.罗伟民已获委任为非执行董事。 香港宽频(01310.HK)：凌浩获委任为执行董事兼董事会主席 香港宽频(01310.HK)：吴育仪获委任为秘书 及授权代表 相关事件 ...

格隆汇9月7日丨中国高速传动(00658.HK)发布公告，国卫会计师事务所有限公司("国卫")已获委任为集 团新任核数师，自2025年9月6日起生效，以填补公司核数师的临时空缺，任期直至公司下届股东周年大 会结束为止。 中国高速传动(00658.HK)：国卫获委任为核数师 中国高速传动(00658.HK)上半年净亏损1.36亿元 同比收 窄74.3% 相关事件 ...

格隆汇9月7日丨映恩生物-B公告，自2025年9月8日起，公司股份将获恒生指数有限公司纳入恒生综合指 数成份股，并被调入沪港通下港股通标的名单。此举代表资本市场对公司表现及价值的高度认同，预计 将扩大投资者基础并增加股份交易流通量。 ...

Core Viewpoint - The company reported a mixed performance in its mid-year results for 2025, with a decline in antibiotic-related revenues but an unexpected strong performance in insulin exports [1][2]. Group 1: Financial Performance - In H1 2025, the company achieved a revenue of 7.52 billion yuan, representing a year-on-year increase of 4.8% [1]. - Gross profit for H1 2025 was 3.92 billion yuan, up 17.3% year-on-year [1]. - Net profit attributable to shareholders reached 1.89 billion yuan, reflecting a year-on-year growth of 27.0% [1]. - Revenue from intermediates was 1.01 billion yuan, down 23.1% year-on-year, while raw material drug revenue was 2.53 billion yuan, down 27.0% [1]. - The combined revenue from formulation products and external licensing was 3.98 billion yuan, showing a significant increase of 65.9% [1]. Group 2: Product Performance - Revenue from antibiotic formulations, including semi-synthetic penicillins and cephalosporins, totaled 799 million yuan, down 10.0% year-on-year [1]. - Insulin products generated 961 million yuan in revenue, marking a substantial increase of 74.5% year-on-year [1]. - The animal health business reported revenue of 565 million yuan, down 15.9% year-on-year [1]. - Other formulations generated 221 million yuan, down 28.9% year-on-year [1]. - External licensing revenue was 1.43 billion yuan [1]. Group 3: Future Outlook - The company has a comprehensive layout in the weight loss sector, with successful launches and applications for GLP-1 products [2]. - The company expects to submit clinical applications for its oral GLP-1 drug UBT48128 in 2026, which shows promising preclinical results [2]. - Revenue projections for 2025-2027 are adjusted to 13.50 billion, 13.90 billion, and 14.75 billion yuan, with expected year-on-year growth rates of -1.86%, 2.97%, and 6.08% respectively [2]. - Net profit forecasts for the same period are set at 2.40 billion, 2.47 billion, and 2.74 billion yuan [2].

Core Viewpoint - ST Pava is currently facing significant challenges due to the investigation of its co-actual controller and director, Zhang Bao, for alleged embezzlement, which has raised concerns about the company's governance and financial practices [1][10]. Company Overview - ST Pava specializes in the research, production, and sales of new energy battery materials, focusing on lithium-ion and sodium-ion battery cathode materials, while also exploring solid-state battery technologies [4]. - Zhang Bao, aged 54, has held various academic and managerial positions, including serving as the general manager and chairman of ST Pava since 2019, before resigning in May 2025 due to health reasons [4][6]. Recent Developments - On August 1, 2025, ST Pava received a notice from law enforcement regarding the investigation of Zhang Bao for embezzlement, and he has since been arrested [1]. - As of June 24, 2025, Zhang Bao was the second-largest shareholder of ST Pava, holding 16.56 million shares, which accounted for 10.41% of the company [5]. - The company reported that other board members and senior management are continuing their duties normally, and the company's control has not changed [1]. Financial Issues - Zhang Bao has been involved in financial discrepancies, including the misappropriation of company funds totaling 191 million yuan, with 30 million yuan already returned to the company [10]. - The company has faced multiple warnings from regulatory bodies regarding inaccurate financial disclosures, including inflated revenue and improper management of company assets [10][11]. Market Performance - As of the last report, ST Pava's stock closed at 10.83 yuan, reflecting a 4.64% increase, with a market capitalization of 1.722 billion yuan [11][13].